<DOC>
	<DOCNO>NCT02268994</DOCNO>
	<brief_summary>24-week phase 3 , multi-center clinical trial , comprise 16-week , randomize , double-blind , placebo-controlled period ( `` Randomized Period '' ) , follow 8-week open-label safety extension period , subject receive KRX-0502 ( ferric citrate ) ( `` Extension Period '' ) .</brief_summary>
	<brief_title>KRX-0502 ( Ferric Citrate ) Treatment IDA Adult Subjects With NDD-CKD</brief_title>
	<detailed_description>24-week phase 3 , multi-center clinical trial , comprise 16-week , randomize , double-blind , placebo-controlled period ( `` Randomized Period '' ) , follow 8-week open-label safety extension period , subject receive KRX-0502 ( ferric citrate ) ( `` Extension Period '' ) . The study consist 14 clinic visit period 24 week . There screen period 14 day ; Approximately 230 subject randomize Randomized Period 1:1 ratio receive either KRX-0502 matching placebo , baseline</detailed_description>
	<mesh_term>Anemia</mesh_term>
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Renal Insufficiency , Chronic</mesh_term>
	<mesh_term>Ferric Compounds</mesh_term>
	<mesh_term>Citric Acid</mesh_term>
	<criteria>1 . Men nonlactating woman negative serum pregnancy test ( woman childbearing potential ) Screening 2 . Age &gt; 18 year 3 . CKD eGFR &lt; 60 mL/min Screening use 4variable Modification Diet Renal Disease ( MDRD ) equation ( limit 20 % target randomization 230 subject eGFR &lt; 15 mL/min ) 4 . Patients intolerant inadequate therapeutic response oral iron supplement ( opinion investigator ) 5 . Hgb &gt; 9.0 g/dL ≤11.5 g/dL Screening 6 . Serum ferritin &lt; 200 ng/mL TSAT &lt; 25 % Screening 7 . Serum iPTH ≤600 pg/mL Screening 8 . Must consume minimum 2 meal per day 9 . Willing able give write informed consent 1 . Serum phosphate &lt; 3.5 mg/dL Screening 2 . Liver enzyme ( ALT/AST ) &gt; X3 time upper limit normal Screening 3 . Symptomatic gastrointestinal bleeding inflammatory bowel disease within 12 week prior Screening 4 . Evidence acute kidney injury requirement dialysis within 12 week prior Screening 5 . Scheduled kidney transplant initiation dialysis plan within 24 week Screening 6 . IV iron administer within 4 week prior Screening 7 . Erythropoiesisstimulating agent ( ESA ) administer within 4 week prior Screening 8 . Blood transfusion within 4 week prior Screening 9 . Receipt investigational drug within 4 week prior Screening 10 . Cause anemia iron deficiency chronic kidney disease 11 . Malignancy ( except nonmelanoma skin cancer diseasefree ≥2 year curative therapy ) 12 . History hemochromatosis 13 . Active drug alcohol dependence abuse ( exclude tobacco use medicinal marijuana ) within 12 month prior Screening evidence abuse ( opinion PI ) 14 . Subjects know allergic reaction previous oral iron therapy 15 . Previous intolerance oral ferric citrate 16 . Psychiatric disorder interferes subject 's ability comply study protocol 17 . Planned surgery hospitalization ( anticipate last &gt; 72 hour ) randomize period trial dialysis access relate surgery . 18 . Any medical condition , opinion PI , render subject unable unlikely complete trial would interfere optimal participation trial produce significant risk subject 19 . Inability cooperate study personnel</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>ferric citrate</keyword>
	<keyword>Chronic kidney disease</keyword>
	<keyword>Anemia</keyword>
</DOC>